Sanofi (SNY) said Wednesday it has opened the Charles Best Building flu vaccine manufacturing facility within the Sanofi Toronto campus that will manufacture its Fluzone High-Dose influenza vaccine.
The expansion, which is worth 925 million Canadian dollars ($663.7 million), comprises CA$415 million in partnership from the Government of Canada and CA$55 million from the Government of Ontario.
The company said the facility is now fully operational and will start production early next year, pending regulatory approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.